Literature DB >> 1973111

Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse.

C F Bunker1, M Johnson, J W Gibb, L G Bush, G R Hanson.   

Abstract

4-Methylaminorex (4-MAX) is an amphetamine analog which has recently gained attention due to its potential as a stimulant of abuse. The present study characterized the acute neurochemical changes elicited after a single dose of 4-MAX. Thus, dose-response and time-response studies were conducted in order to assess the effects of this drug on monoaminergic and neuropeptide systems in extrapyramidal and limbic structures. The most dramatic responses in the dose-effect experiments (animals killed 3 h after treatment) were a 2-fold increase in neostriatal homovanillic acid levels and a decrease in neostriatal tryptophan hydroxylase activity to 33% of control in the 20 mg/kg group. Because all animals in the 20 mg/kg group experienced convulsions, 10 mg/kg was used for the time-response studies. The most striking effects in these studies included a reduction in dopamine concentrations to 71% of control, and an increase to 270% of control in the concentrations of dihydroxyphenylacetic acid 30 min after 4-MAX administration. In addition, neostriatal neurotensin and dynorphin A levels increased to approximately 200 and 400% of control, respectively, 18 h after a 10 mg/kg dose. These data suggest that 4-MAX is a potent dopamine releaser, which decreases tryptophan hydroxylase activity in a manner similar to other amphetamine-related drugs. However, in contrast to other amphetamine analogs, 4-MAX has potent convulsant actions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973111     DOI: 10.1016/0014-2999(90)90597-y

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni').

Authors:  Simon D Brandt; Michael H Baumann; John S Partilla; Pierce V Kavanagh; John D Power; Brian Talbot; Brendan Twamley; Olivia Mahony; John O'Brien; Simon P Elliott; Roland P Archer; Julian Patrick; Kuldip Singh; Nicola M Dempster; Simon H Cosbey
Journal:  Drug Test Anal       Date:  2014-05-19       Impact factor: 3.345

Review 2.  DARK Classics in Chemical Neuroscience: Aminorex Analogues.

Authors:  Julian Maier; Felix P Mayer; Simon D Brandt; Harald H Sitte
Journal:  ACS Chem Neurosci       Date:  2018-10-05       Impact factor: 5.780

3.  Characterization of a recently detected halogenated aminorex derivative: para-fluoro-4-methylaminorex (4'F-4-MAR).

Authors:  D Fabregat-Safont; X Carbón; M Ventura; I Fornís; F Hernández; M Ibáñez
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.